Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
Plasma Amyloid and in vivo Brain Amyloid in Late Middle-Aged Hispanics.
复制标题
DOI：
10.3233/jad-210391
复制
发表时间：
2022
影响因子：
4
通讯作者：
Luchsinger, Jose A.
中科院分区：
文献类型：
--
作者：
Rippon, Brady;Palta, Priya;Tahmi, Mouna;Sherwood, Greysi;Soto, Luisa;Cespedes, Sandino;Mesen, Yanette;He, Hengda;Laing, Krystal;Moreno, Herman;Teresi, Jeanne;Razlighi, Qolamreza;Brickman, Adam M.;Zetterberg, Henrik;Luchsinger, Jose A.
通过脑脊液和淀粉样蛋白脑成像可以确定淀粉样蛋白阳性，但这些方法具有侵入性且昂贵。为了将使用单分子阵列 (Simoa™) 测定法测量的血浆淀粉样蛋白 β (Aβ) 与使用正电子发射断层扫描 (PET) 测量的体内大脑 Aβ 联系起来，检查血浆 Aβ 预测大脑 Aβ 阳性的准确性，以及 APOE-ε4 与血浆 Aβ 的关系。我们对 345 名中年西班牙裔男性和女性（年龄 64 岁，72% 女性）进行了横断面分析。我们的主要血浆变量是用 Simoa 测量的 Aβ42/Aβ40 比率。通过连续、明确地检查 18F-Florbetaben PET，将脑 Aβ 负荷作为整体 SUVR 进行测量。血浆 Aβ42/Aβ40 比率与总体 Aβ SUVR（β = − 0.13，95% 置信区间 (CI)：−0.23，−0.03；p = 0.013）和 Aβ 阳性（比值比：0.59，95% CI：0.38，0.91；p = 0.016）呈负相关，独立于人口统计和 APOE-ε4。 ROC 曲线（AUC = 0.73，95% CI：0.64，0.82；p < 0.0001）显示，血浆 Aβ42/Aβ40 比率与脑 Aβ 阳性率相关的最佳阈值为 0.060，敏感性为 82.4%，特异性为 62.8%。 APOE-ε4 携带者具有较低的 Aβ42/Aβ40 比值和较高的 Aβ 阳性率（Aβ42/Aβ40 比值阈值为 0.060）。使用 Simoa 测定的血浆 Aβ42/Aβ40 比率与体内脑淀粉样蛋白的相关性较弱，并且当体内成像不可行时，筛选淀粉样蛋白阳性和研究脑淀粉样蛋白负荷危险因素的准确性有限。
Determining amyloid positivity is possible with cerebrospinal fluid and brain imaging of amyloid, but these methods are invasive and expensive. To relate plasma amyloid β (Aβ), measured using Single-molecule array (Simoa™) assays, to in-vivo brain Aβ, measured using Positron Emission Tomography (PET), examine the accuracy of plasma Aβ to predict brain Aβ positivity, and the relation of APOE-ε4 with plasma Aβ. We performed a cross-sectional analysis in a cohort of 345 late middle-aged Hispanic men and women (age 64 years, 72% women). Our primary plasma variable was Aβ42/Aβ40 ratio measured with Simoa. Brain Aβ burden was measured as global SUVR with 18F-Florbetaben PET examined continuously and categorically. Plasma Aβ42/Aβ40 ratio was inversely associated with global Aβ SUVR (β = − 0.13, 95% Confidence Interval (CI): −0.23, −0.03; p = 0.013) and Aβ positivity (Odds Ratio: 0.59, 95% CI: 0.38, 0.91; p = 0.016), independent of demographics and APOE-ε4. ROC curves (AUC = 0.73, 95% CI: 0.64, 0.82; p < 0.0001), showed that the optimal threshold for plasma Aβ42/Aβ40 ratio in relation to brain Aβ positivity was 0.060 with a sensitivity of 82.4% and specificity of 62.8%. APOE-ε4 carriers had lower Aβ42/Aβ40 ratio and a higher Aβ positivity determined with the Aβ42/Aβ40 ratio threshold of 0.060. plasma Aβ42/Aβ40 ratio assayed using Simoa is weakly correlated with in-vivo brain amyloid, and has limited accuracy to screen for amyloid positivity and for studying risk factors of brain amyloid burden when in-vivo imaging is not feasible.